Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabazitaxel in AR-V7 Positive mCRPC
NCT02621190Phase 2Withdrawn
- Sponsor
- Erasmus MC
- Start
- Feb 2016
- Primary completion
- Feb 2019
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 2, open-label trial of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Prostate specific antigen (PSA) response rate at 12 weeks. Planned start Feb 2016; status: withdrawn.
02
Drugs
cabazitaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02621190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02621190.